New chemo cocktail aims to boost survival in kids with rare lymphoma

NCT ID NCT02845882

Ongoing Disease control Sponsor: Children's Cancer Group, China Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial is testing a modified chemotherapy regimen for 150 Chinese children and adolescents newly diagnosed with lymphoblastic lymphoma. The goal is to improve event-free survival compared to previous results. Participants receive a combination of drugs including prednisone, vincristine, and others over several phases.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: combination chemotherapy (prednisone, vincristine, pegylated-asparaginase, cytarabine, cyclophosphamide, daunorubicin, 6-mercaptopurine, methotrexate)
What this could lead to: If successful, this could improve survival rates for children with lymphoblastic lymphoma in China.
What could go wrong: This is an early-phase trial with a small sample size, and the modified regimen may not prove more effective than standard therapy. Chemotherapy carries risks like infection and organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOBLASTIC LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lymphoblastic lymphoma Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOBLASTIC LYMPHOMA

Contacts and locations

Locations

Shanghai Children's Medical Center

Shanghai, 200127, China
West China Second University Hospital

Chengdu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.